Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized, multicenter, open-label, modified dose-ascension, parallel study of the safety, tolerability and efficacy of oral SCIO-469 in patients with myelodysplastic syndromes

Trial Profile

A randomized, multicenter, open-label, modified dose-ascension, parallel study of the safety, tolerability and efficacy of oral SCIO-469 in patients with myelodysplastic syndromes

Completed
Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2013

At a glance

  • Drugs Talmapimod (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Scios
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 29 Aug 2008 Integrated NCT00744432, from clincialtrials.gov: added IDs, patient number.
    • 29 Aug 2008 Integrated NCT00744432, from clincialtrials.gov: added IDs, patient number.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top